|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Postpartum Hemorrhage; Hemorrhage
ETHAMSYLATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 24YL531VOH |
| Molecule Type: Small molecule |
| Molecular Formula: C10H17NO5S |
| Molecular Weight: 263.31 |
| AlogP: 0.34 |
| PSA: 94.83 |
| HBD: 3.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Thyroid Diseases
BENZYLTHIOURACIL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: PZ35LUM333 |
| Molecule Type: Small molecule |
| Molecular Formula: C11H10N2OS |
| Molecular Weight: 218.28 |
| AlogP: 2.06 |
| PSA: 46.01 |
| HBD: 2.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
IOTHALAMATE SODIUM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: KDN276D83N |
| Molecule Type: Small molecule |
| Molecular Formula: C11H8I3N2NaO4 |
| Molecular Weight: 635.9 |
| AlogP: 2.52 |
| PSA: 95.5 |
| HBD: 3.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MEXENONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: ET1UGF4A0B |
| Molecule Type: Small molecule |
| Molecular Formula: C15H14O3 |
| Molecular Weight: 242.27 |
| AlogP: 2.94 |
| PSA: 46.53 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CADEXOMER IODINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
POLYVINYL ALCOHOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 532B59J990 |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FLUNITRAZEPAM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 620X0222FQ |
| Molecule Type: Small molecule |
| Molecular Formula: C16H12FN3O3 |
| Molecular Weight: 313.29 |
| AlogP: 2.55 |
| PSA: 75.81 |
| HBD: 0.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms, Male; Neoplasms; Cocaine-Related Disorders; Hernias, Diaphragmatic, Congenital; Obesity; Schizophrenia; Depressive Disorder
TRYPTOPHAN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8DUH1N11BX |
| Molecule Type: Small molecule |
| Molecular Formula: C11H12N2O2 |
| Molecular Weight: 204.23 |
| AlogP: 1.12 |
| PSA: 79.11 |
| HBD: 3.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Antimicrobial preservative, used in vaccines
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
THIMEROSAL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 2225PI3MOV |
| Molecule Type: Small molecule |
| Molecular Formula: C9H9HgNaO2S |
| Molecular Weight: 404.82 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Severe Acute Respiratory Syndrome; Virus Diseases
INOSINE PRANOBEX
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: W1SO0V223F |
| Molecule Type: Small molecule |
| Molecular Formula: C52H78N10O17 |
| Molecular Weight: 1115.25 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder; Hypotension, Orthostatic; Inflammation; Radiodermatitis; Acute Lung Injury; Brain Injuries; Cognitive Dysfunction; Heart Diseases; Hernias, Diaphragmatic, Congenital; Hypotension; Sepsis; Shock; Shock, Septic; Cardiovascular Diseases
NOREPINEPHRINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: X4W3ENH1CV |
| Molecule Type: Small molecule |
| Molecular Formula: C8H11NO3 |
| Molecular Weight: 169.18 |
| AlogP: 0.09 |
| PSA: 86.71 |
| HBD: 4.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leiomyoma; Myoma
ULIPRISTAL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 6J5J15Q2X8 |
| Molecule Type: Small molecule |
| Molecular Formula: C28H35NO3 |
| Molecular Weight: 433.59 |
| AlogP: 4.97 |
| PSA: 57.61 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acne Vulgaris
ALUMINIUM OXIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: LMI26O6933 |
| Molecule Type: Small molecule |
| Molecular Formula: Al2O3 |
| Molecular Weight: 101.96 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
HOMATROPINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8QS6WCL55Z |
| Molecule Type: Small molecule |
| Molecular Formula: C16H21NO3 |
| Molecular Weight: 275.35 |
| AlogP: 1.89 |
| PSA: 49.77 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FENCLOZIC ACID
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 58SRQ4DV53 |
| Molecule Type: Small molecule |
| Molecular Formula: C11H8ClNO2S |
| Molecular Weight: 253.71 |
| AlogP: 3.09 |
| PSA: 50.19 |
| HBD: 1.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Progesterone receptor modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CHLORMADINONE ACETATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 0SY050L61N |
| Molecule Type: Small molecule |
| Molecular Formula: C23H29ClO4 |
| Molecular Weight: 404.93 |
| AlogP: 4.75 |
| PSA: 60.44 |
| HBD: 0.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Status Epilepticus
PARALDEHYDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: S6M3YBG8QA |
| Molecule Type: Small molecule |
| Molecular Formula: C6H12O3 |
| Molecular Weight: 132.16 |
| AlogP: 1.09 |
| PSA: 27.69 |
| HBD: 0.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Acne Vulgaris; Helminthiasis
BITHIONOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: AMT77LS62O |
| Molecule Type: Small molecule |
| Molecular Formula: C12H6Cl4O2S |
| Molecular Weight: 356.06 |
| AlogP: 5.86 |
| PSA: 40.46 |
| HBD: 2.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
FERROUS GLYCINE SULFATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 56PS9HY5XI |
| Molecule Type: Small molecule |
| Molecular Formula: C4H10FeN2O8S |
| Molecular Weight: 302.04 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Abdominal Pain; Digestive System Diseases
BUTYLSCOPOLAMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 2Z3E1OF81V |
| Molecule Type: Small molecule |
| Molecular Formula: C21H30NO4+ |
| Molecular Weight: 360.47 |
| AlogP: 2.23 |
| PSA: 59.06 |
| HBD: 1.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Serotonin transporter inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Erectile Dysfunction; Sexual Dysfunction, Physiological
DAPOXETINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: GB2433A4M3 |
| Molecule Type: Small molecule |
| Molecular Formula: C21H23NO |
| Molecular Weight: 305.42 |
| AlogP: 4.91 |
| PSA: 12.47 |
| HBD: 0.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
PIFOXIME
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 5947ECZ7WH |
| Molecule Type: Small molecule |
| Molecular Formula: C15H20N2O3 |
| Molecular Weight: 276.34 |
| AlogP: 2.28 |
| PSA: 62.13 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases
MEFRUSIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: X1NS9SNS92 |
| Molecule Type: Small molecule |
| Molecular Formula: C13H19ClN2O5S2 |
| Molecular Weight: 382.89 |
| AlogP: 1.18 |
| PSA: 106.77 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor inverse agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Conjunctivitis, Allergic; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria; Eye Manifestations; Hypersensitivity
BILASTINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: PA1123N395 |
| Molecule Type: Small molecule |
| Molecular Formula: C28H37N3O3 |
| Molecular Weight: 463.62 |
| AlogP: 4.86 |
| PSA: 67.59 |
| HBD: 1.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INTRAUTERINE
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
COPPER
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 789U1901C5 |
| Molecule Type: Small molecule |
| Molecular Formula: Cu+2 |
| Molecular Weight: 63.55 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CYCLOFENIL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: J468V64WZ1 |
| Molecule Type: Small molecule |
| Molecular Formula: C23H24O4 |
| Molecular Weight: 364.44 |
| AlogP: 5.3 |
| PSA: 52.6 |
| HBD: 0.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DITHIAZANINE IODIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8OEC3RA07X |
| Molecule Type: Small molecule |
| Molecular Formula: C23H23IN2S2 |
| Molecular Weight: 518.49 |
| AlogP: 6.25 |
| PSA: 7.12 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Tobacco Use Disorder
NICOTINE BITARTRATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: R7M676M8YV |
| Molecule Type: Small molecule |
| Molecular Formula: C18H30N2O14 |
| Molecular Weight: 498.44 |
| AlogP: 1.85 |
| PSA: 16.13 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M2 positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
ALCURONIUM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: S8U3J5W06N |
| Molecule Type: Small molecule |
| Molecular Formula: C44H50N4O2+2 |
| Molecular Weight: 666.91 |
| AlogP: 5.48 |
| PSA: 46.94 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cyclooxygenase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CLOMETACIN
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: L9M34YK25C |
| Molecule Type: Small molecule |
| Molecular Formula: C19H16ClNO4 |
| Molecular Weight: 357.79 |
| AlogP: 3.93 |
| PSA: 68.53 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Severe Acute Respiratory Syndrome; Schizophrenia; Malaria
ARTEMISININ
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 9RMU91N5K2 |
| Molecule Type: Small molecule |
| Molecular Formula: C15H22O5 |
| Molecular Weight: 282.34 |
| AlogP: 2.39 |
| PSA: 53.99 |
| HBD: 0.0 |
| HBA: |
| #RotB: 0.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CYCLOBARBITAL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 0M8A98AD9H |
| Molecule Type: Small molecule |
| Molecular Formula: C12H16N2O3 |
| Molecular Weight: 236.27 |
| AlogP: 1.25 |
| PSA: 75.27 |
| HBD: 2.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Delta(24)-sterol reductase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TRIPARANOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 63S8C3RXGS |
| Molecule Type: Small molecule |
| Molecular Formula: C27H32ClNO2 |
| Molecular Weight: 438.01 |
| AlogP: 5.85 |
| PSA: 32.7 |
| HBD: 1.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DILOXANIDE FUROATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: YP4N72IW34 |
| Molecule Type: Small molecule |
| Molecular Formula: C14H11Cl2NO4 |
| Molecular Weight: 328.15 |
| AlogP: 3.27 |
| PSA: 59.75 |
| HBD: 0.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
BUTETHAL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: OHZ8QAW6YC |
| Molecule Type: Small molecule |
| Molecular Formula: C10H16N2O3 |
| Molecular Weight: 212.25 |
| AlogP: 0.94 |
| PSA: 75.27 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA disrupting agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Neoplasms
MITOBRONITOL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 5UP30YED7N |
| Molecule Type: Small molecule |
| Molecular Formula: C6H12Br2O4 |
| Molecular Weight: 307.97 |
| AlogP: -0.78 |
| PSA: 80.92 |
| HBD: 4.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |